UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~Report~~report (Date of earliest event reported): ~~March~~ 14April 28, 2023

IVERIC bio, Inc.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~ charter)

Delaware

001-36080

20-8185347

~~001-36080~~

~~20-8185347~~

(State or Other Jurisdictionof Incorporation)

(CommissionFile Number)

(IRS EmployerIdentification No.)

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

8 Sylvan Way

Parsippany, NJ 07054

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 474-6755

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	~~Trading Symbol(s)~~	Name of each exchange on which registered	~~Name of each exchange on which registered~~
Common Stock, $0.001 par value per share		ISEE		The Nasdaq Global Select Market
Common Stock, par value $0.001 per share	ISEE		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company ☐~~

If¨ anEmerging ~~emerging~~Growth growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Company

~~Item~~¨ ~~1.01.~~If ~~Entry~~an ~~into~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) ~~Material~~of ~~Definitive~~the ~~Agreement~~Exchange Act.

~~Commercial~~Item ~~Manufacturing~~1.01 ~~and~~Entry ~~Supply~~into a Material Definitive Agreement.

On ~~March 14~~April 28, 2023, IVERIC bio, Inc. (~~"IVERIC" or~~ the “Company”) entered into aan ~~Commercial~~Agreement ~~Manufacturing~~ and ~~Supply~~Plan ~~Agreement~~of Merger (the “Merger Agreement”) with ~~Agilent~~Astellas ~~Technologies,~~US Holding, Inc., a Delaware corporation (~~"Agilent"~~“Parent”), ~~relating~~Berry toMerger ~~the~~Sub, Inc., ~~commercial~~a ~~manufacturing~~Delaware corporation and ~~supply~~a ofwholly ~~avacincaptad~~owned ~~pegol~~subsidiary of Parent (~~"ACP"~~“Merger Sub”), ~~drug~~and ~~substance~~solely as provided by Section ‎8.10(b) of the ~~"Agilent~~Merger Agreement", Astellas Pharma Inc., a company organized under the laws of Japan (“Guarantor”), providing for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.

~~Pursuant~~At to the ~~Agilent~~Effective ~~Agreement,~~Time of ~~Agilent~~the ~~has~~Merger, ~~agreed~~each toshare ~~manufacture~~of ~~and~~common ~~supply to IVERIC~~stock, ~~and~~par ~~IVERIC~~value ~~has~~$0.001 ~~agreed~~per ~~to purchase from Agilent~~share, ~~a specified percentage~~ of ~~its~~the ~~commercial~~Company ~~requirements~~issued inand ~~the~~outstanding ~~United~~as ~~States~~ of ~~the~~immediately ~~active~~prior ~~pharmaceutical~~to the ~~ingredient~~Effective Time (~~"API")~~other ~~used~~than inExcluded ~~ACP.~~Shares ~~The~~and ~~Agilent~~Dissenting ~~Agreement~~Shares) ~~has~~will anbe ~~initial~~cancelled ~~term~~and ofautomatically ~~seven~~converted ~~years~~into ~~from~~ the ~~date~~right ofto receive ~~regulatory~~cash ~~approval~~ in ~~the~~an ~~United~~amount ~~States~~equal ofto ~~the Company's New Drug Application for ACP~~$40.00, ~~followed~~without byinterest ~~successive~~(the ~~two-year~~“Merger ~~automatic~~Consideration”) ~~renewal~~and ~~periods,~~subject ~~absent~~to ~~non-renewal~~any ~~or termination by either party in accordance with the terms~~ withholding of ~~the Agilent Agreement~~taxes. The ~~Agilent~~Merger Agreement ~~provides~~requires ~~for~~Guarantor ~~pricing~~to ~~for~~guarantee the ~~API~~covenants, ~~based~~obligations on(including apayment ~~per~~obligations) ~~batch~~and orliabilities applicable ~~per~~to ~~gram basis~~Parent, ~~depending~~Merger onSub or the ~~scale~~Surviving ~~for~~Corporation, ~~which~~as ~~the~~applicable, ~~Company~~under ~~orders~~ the ~~API~~Merger Agreement.

~~IVERIC~~Consummation ~~may~~of ~~cancel~~the ~~any~~Merger is ~~purchase~~subject ~~order~~to ~~under~~customary closing conditions, including, without limitation, the ~~Agilent~~absence ~~Agreement~~of atcertain ~~any~~legal ~~time~~impediments, ~~subject~~no toMaterial ~~the~~Adverse Effect ~~payment~~having ofoccurred ~~specified~~since ~~cancellation~~the ~~fees. IVERIC~~signing ~~may~~of ~~terminate~~ the ~~Agilent~~Merger Agreement, in the ~~event~~expiration ~~that~~or ittermination ~~cannot~~of ~~commercialize~~the ~~ACP~~required ~~due~~waiting toperiods ~~regulatory~~under the orHart-Scott-Rodino ~~other~~Antitrust ~~medical,~~Improvements ~~scientific~~Act orof ~~legal~~1976, ~~reasons. Agilent~~as ~~may~~amended, ~~terminate~~and ~~the~~any ~~Agilent~~other ~~Agreement~~Specified inAntitrust ~~the~~Authority, ~~event~~solely ~~that~~to ~~IVERIC~~the ~~does~~extent the ~~not,~~approval ~~over~~of aany ~~specified~~such ~~period,~~authority ~~purchase~~is ~~and~~required ~~take~~in ~~delivery~~connection ofwith the ~~agreed~~Merger, ~~upon~~and ~~minimum~~approval ~~requirements~~by ofthe ~~API~~Company’s stockholders. ~~Each~~ ~~party~~The ~~also~~parties expect ~~has~~the Merger and the ~~right~~other totransactions ~~terminate~~contemplated by the ~~Agilent~~Merger Agreement ~~for~~to ~~other~~close ~~customary~~in ~~reasons~~the ~~such~~third ascalendar ~~material~~quarter ~~breach~~of ~~and bankruptcy~~2023.

The ~~Agilent~~Company has made customary representations and warranties in the Merger Agreement ~~contains~~and ~~provisions~~has ~~relating~~agreed to ~~compliance~~customary bycovenants ~~Agilent~~regarding ~~with~~the ~~current~~operation ~~Good~~of ~~Manufacturing~~the business ~~Practices,~~of ~~cooperation~~the byCompany ~~Agilent~~and inits ~~connection~~Subsidiaries ~~with~~prior ~~marketing~~to ~~applications~~the Effective Time. The Company is also subject to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and ~~other~~to ~~regulatory~~provide ~~filings~~non-public ~~for~~information ~~ACP~~to, ~~indemnification,~~and ~~confidentiality~~participate in discussions and engage in negotiations with, ~~dispute~~third ~~resolution~~parties ~~and~~regarding ~~other~~alternative acquisition proposals, with customary ~~matters~~exceptions ~~for~~to anallow ~~agreement~~the Board of ~~this~~Directors ~~kind~~to exercise its fiduciary duties.

~~IVERIC~~The ~~plans~~Merger Agreement contains certain termination rights for the Company and Parent. Subject to ~~file~~certain limitations, the ~~Agilent~~Company or Parent may terminate the Merger Agreement asif anthe ~~exhibit~~Merger tois ~~its~~not ~~Quarterly~~consummated ~~Report~~by midnight Eastern Time, on ~~Form~~October 27, 102023, subject to an automatic 90-Qday ~~for~~extension in the ~~quarter~~event ~~ending~~that ~~March~~all ~~31,~~conditions ~~2023,~~other ~~with~~than ~~confidential~~antitrust ~~portions~~approval ~~redacted.~~are ~~The~~not ~~foregoing~~obtained ~~description~~or iswaived ~~qualified~~as of such date and a second automatic 90-day extension thereafter in ~~its~~the ~~entirety~~event bythat ~~reference~~all toconditions other than the ~~complete~~required ~~text~~antitrust approvals have been obtained or waived as of ~~the~~such extended ~~Agilent~~date ~~Agreement~~(the ~~when~~“End ~~filed~~Date”).

Upon termination of the Merger Agreement, under specified circumstances, the Company will be required to pay Parent a termination fee of $222,370,000. Such circumstances include where the Merger Agreement is terminated (i) in connection with the Company accepting a Superior Offer approved by the Board of Directors, (ii) due to the Board of Directors’ change or withdrawal of, or failure to reaffirm, its recommendation of the Merger, or (iii) because the Board of Directors or the Company intentionally breach their non-solicit obligations under the Merger Agreement in any material respects. This termination fee will also be payable if the Merger Agreement is terminated because the Company’s stockholders did not vote to adopt the Merger Agreement, the Merger is not consummated before the End Date, or the Company breaches its representations, warranties or covenants in a manner that would cause the related closing conditions to not be met, and prior to any such termination, a proposal to acquire at least 50% of the Company’s stock or assets is communicated to the Board of Directors or publicly disclosed and the Company enters into an agreement for, or consummates, a transaction contemplated by such proposal within one year of termination.

At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is less than the Merger Consideration (each, an “In the Money Option”), will be cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the Merger Consideration over (y) the exercise price payable per share under such In the Money Option, multiplied by (B) the total number of shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). In addition, at the Effective Time, each Company Option other than an In the Money Option that is then outstanding and unexercised, whether or not vested, will be cancelled with no consideration payable in respect thereof. At the Effective Time, each then outstanding Company RSU will be canceled and the holder thereof will be entitled to receive a cash payment equal to the product of (x) the Merger Consideration and (y) the number of shares subject to such Company RSU. At the Effective Time, each then outstanding Company PSU will be canceled and converted into a cash-based award, which will entitle the holder thereof to receive a cash payment equal to the product of (x) the Merger Consideration, and (y) the number of shares subject to such Company PSU, subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding Company PSU immediately prior to the Effective Time.

The representations, warranties and covenants of the Company contained in the Merger Agreement have been made solely for the benefit of Parent and Merger Sub. In addition, such representations, warranties and covenants (i) have been made only for purposes of the Merger Agreement, (ii) have been qualified by (a) subject to certain terms and conditions, matters specifically disclosed in the Company’s filings with the United States Securities and Exchange Commission (“SEC”) prior to the date of the Merger Agreement and (b) confidential disclosures made to Parent and Merger Sub in the disclosure letter delivered in connection with the Merger Agreement, (iii) are subject to materiality qualifications contained in the Merger Agreement which may differ from what may be viewed as material by investors, and (iv) have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as fact. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding the terms of the Merger Agreement, and not to provide investors with any other factual information regarding the Company or its business.

Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated by reference into, the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents that the Company files with the SEC.

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement a copy of which is attached hereto as Exhibit 2.1, and the terms of which are incorporated herein by reference.

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On April 28, 2023, the Board approved an amendment to the Company’s existing Amended and Restated Bylaws (the “Bylaws”) to add a new Article V, Section 9 forum selection provision (the “Forum Selection Amendment”).

The Forum Selection Amendment provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a duty (including any fiduciary duty) owed by any current or former director, officer, stockholder, employee or agent of the Company to the Company or the Company’s stockholders, (iii) any action asserting a claim against the Company or any current or former director, officer, stockholder, employee or agent of the Company arising out of or relating to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation of the Company or the Bylaws (each, as in effect from time to time), or (iv) any action asserting a claim against the Company or any current or former director, officer, stockholder, employee or agent of the Company governed by the internal affairs doctrine of the State of Delaware; provided, however, that, in the event that the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding, the sole and exclusive forum for such action or proceeding will be another state or federal court located within the State of Delaware, in each such case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party named as a defendant therein.

This summary is qualified in its entirety by reference to the Forum Selection Amendment, which is filed as Exhibit 3.1 hereto and incorporated by reference herein.

Item 8.01

Other Events.

On April 30, 2023, the Company and Guarantor issued a joint press release announcing entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 to the Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits

(d)

Exhibits.

Exhibit No.		Description

2.1		Agreement and Plan of Merger, dated as of April 28, 2023, by and among Astellas US Holding, Inc., Berry Merger Sub, Inc., IVERIC bio, Inc. and, solely as provided by Section ‎8.10(b) therein, Astellas Pharma Inc.*

3.1		Amendment to IVERIC bio, Inc.’s Amended and Restated Bylaws, dated April 28, 2023

99.1		Joint Press Release issued by IVERIC bio, Inc. and Astellas Pharma Inc. on April 30, 2023

* Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.

* * *

Forward Looking Statements

All statements in this Current Report on Form 8-K, other than statements of historical fact, are statements that could be deemed “forward-looking statements.” In some cases, forward-looking statements may be identified by terminology such as “believe,” “may,” “will,” “should”, “predict”, “goal”, “strategy”, “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” “seek” and similar expressions and variations thereof. The Company intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. Private Securities Litigation Reform Act of 1995.

This Current Report on Form 8-K contains “forward-looking statements” relating to, among other things, the proposed acquisition of the Company, by way of a merger of a subsidiary of Guarantor (together with its subsidiaries, “Astellas”) with and into the Company and the objectives of such proposed acquisition, Astellas’ and the Company’s beliefs and expectations regarding the potential benefits sought to be achieved by Astellas’ proposed acquisition of the Company, the potential effects of the proposed acquisition on both Astellas and the Company, the expected benefits and success of the Company’s product candidates, the anticipated timing for approval of ACP, the anticipated financing of the proposed acquisition, and the anticipated timing of completion of the proposed acquisition, each of which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Risks and uncertainties include, among other things, risks related to the ability of the Company and Astellas to complete the transactions contemplated by the Merger Agreement; the satisfaction or waiver of the conditions to closing the proposed acquisition set forth in the Merger Agreement (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company’s stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the timing and nature of regulatory filings for the Company’s product candidates, and the possibility of a termination of the Merger Agreement; the possibility that competing offers to acquire the Company may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the Company’s business and products will not be integrated with those of Astellas successfully; the effects of disruption from the transactions contemplated by the Merger Agreement on the Company’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Astellas’ or the Company’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or the Company’s business; risks related to the financing of the acquisition; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data is subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for the Company’s pipeline products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety or other matters that could affect the availability or commercial potential of such products; expectations for personnel and human capital matters; and competitive developments.

Moreover, Astellas and the Company operate in very competitive and rapidly changing environments, and new risks emerge from time to time. Astellas and the Company have based these forward-looking statements on their current expectations and projections about future events and trends that they believe may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs of Astellas and the Company, but they cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of biotechnology development and potential regulatory approval. The foregoing factors are not exhaustive. You should also carefully consider other risks and uncertainties that may affect the business of the Company, including those described in the “Forward-Looking Statements”, “Summary of Principal Risk Factors”, and “Risk Factors” sections of the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC, all of which are available on the SEC’s website at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements and Astellas and the Company assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law.

Additional Information and Where to Find It

In connection with the proposed acquisition, the Company will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed acquisition. This document is not a substitute for the proxy statement or any other document which the Company may file with the SEC. The definitive proxy statement will be mailed to the Company’s stockholders in connection with the proposed acquisition. This Current Report on Form 8-K is not a substitute for the proxy statement or any other document that may be filed by the Company with the SEC. BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Any vote in respect of resolutions to be proposed at the Company’s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in the Company’s proxy statement. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov, and all documents filed by the Company with the SEC are available to all stockholders of the Company free of charge at https://investors.ivericbio.com/financial-information/sec-filings or by contacting the Company’s investor relations department at the following:

IVERIC bio, Inc.

Kathy Galante
Senior Vice President, Investor Relations
kathy.galante@ivericbio.com

Participants in the Solicitation

The Company, and its directors, executive officers and other members of management and certain other people may be deemed to be participants in the solicitation of proxies in connection with the proposed acquisition. Information about the Company’s directors and executive officers is included in the proxy statement for the Company’s annual meeting of stockholders for 2023, filed with the SEC on April 5, 2023. Additional information regarding these persons and their interests in the merger will be included in the proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents, when available, can be obtained free of charge from the sources indicated above.

Important Additional Information

This Current Report on Form 8-K is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of the Company’s common stock or any other securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IVERIC bio, Inc.
Date: March 20, 2023	By:	/s/ David F. Carroll
		David F. Carroll
		Senior Vice President, Chief Financial Officer and Treasurer

Date: May 1, 2023

3IVERIC bio, Inc. By: /s/ David F. Carroll Name: David F. Carroll Title: Senior Vice President, Chief Financial Officer and Treasurer

Filing Compare · IVERIC bio, Inc.